01 Increasing Adoption of Rapid and Portable Molecular Testing Platforms Portable PCR platforms, integrated sample-to-result workflows, and cartridge-based systems are improving turnaround times and supporting use across hospitals, urgent care centers, physician offices, decentralized laboratories, and remote healthcare settings. In February 2026, the FDA granted CLIA waiver for the LEX Diagnostics VELO Respiratory Test, supporting broader use of rapid molecular respiratory testing in decentralized care settings.
02 Growing Integration of Multiplex and Connected Molecular Diagnostic Solutions Diagnostic platforms are increasingly combining multiplex detection with automated workflows and digital connectivity to provide broader clinical information from a single patient sample. Multiplex molecular testing can differentiate pathogens with overlapping symptoms, while connected systems enable results to be shared with healthcare records and remote-care platforms, improving the speed and coordination of clinical decision-making. In February 2025, Aptitude received U.S. FDA Emergency Use Authorization for its Metrix COVID/Flu multiplex molecular test, combining rapid molecular detection with point-of-care and over-the-counter testing capabilities.
01 Rising Burden of Infectious Diseases Increases Need for Accessible Molecular Diagnostics The continued prevalence of respiratory and other infectious diseases is increasing the need for accessible diagnostic solutions across hospitals, outpatient facilities, urgent care centers, and community healthcare settings. Infectious disease outbreaks and the need for timely identification of pathogens are encouraging healthcare systems to strengthen diagnostic capacity and expand access to molecular testing technologies. This underlying clinical need supports continued demand for point-of-care molecular diagnostic platforms.
01 High Costs of Molecular Diagnostic Systems and Consumables Can Limit Adoption Point-of-care molecular platforms require investment in analyzers, cartridges, reagents, quality-control procedures, connectivity infrastructure, and operator training. Recurring consumable costs can further increase the total cost of testing, making advanced molecular systems difficult to deploy in healthcare facilities with constrained budgets, particularly in low-resource and emerging markets.
01 Expansion of Point-of-Care Molecular Diagnostics Across Women's Health and Preventive Screening Creates New Growth Opportunities The expansion of molecular testing into women's health, sexually transmitted infections, cervical cancer screening, and preventive diagnostics is creating new opportunities beyond traditional infectious disease applications. Self-collection, decentralized screening, and near-patient testing can improve access to molecular diagnostics while enabling faster follow-up and treatment decisions in community and outpatient settings.
01 Maintaining Accuracy and Regulatory Compliance Across Decentralized Testing Environments Creates Challenges Expanding molecular diagnostics beyond centralized laboratories requires consistent analytical performance despite differences in operators, sample handling, environmental conditions, and healthcare infrastructure. In August 2026, the FDA issued a CLIA waiver decision for the Cepheid GeneXpert Edge X System, illustrating the regulatory validation required for molecular diagnostic systems intended for use in decentralized testing environments.
March 2026 Thermo Fisher Scientific expanded its transplant diagnostics portfolio with enhanced molecular testing solutions, including improved HLA typing and donor-recipient compatibility testing technologies to support transplant decision-making.
January 2026 CareDx expanded its transplant diagnostics ecosystem with advancements in non-invasive monitoring solutions, including molecular-based testing platforms designed to detect organ rejection risk and improve post-transplant patient management.
October 2025 Bio-Rad Laboratories expanded its immunohematology and transplant diagnostics offerings with advanced laboratory testing solutions supporting HLA analysis, antibody detection, and transplant compatibility assessment.
August 2025 QIAGEN expanded its molecular diagnostics portfolio with new genomic testing solutions supporting transplant monitoring, immune profiling, and personalized patient management applications.